Harmony Biosciences Holdings, Inc.
HRMYUnited States
40 filed reports · 341 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
40 reports · Sep 2020 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 30 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 18 | 3,110 | Sep 2020 to Jun 2026 |
| Current · 8-KSEC EDGAR | 15 | 30 | Dec 2023 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 6 | 2,313 | Dec 2020 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 1 | 1 | Dec 2023 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 4, 2026 | 2 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 4, 2026 | 369 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 16, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 251 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 7, 2026 | 2 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 24, 2026 | 2 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 735 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 4, 2025 | 2 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 260 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 23, 2025 | 2 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 5, 2025 | 2 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 172 | Open |
Financial data
341 concepts · 5,454 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial328 concepts · 5,269 facts · Sep 2017 to Jul 2026
- Research and development40 · Dec 2019 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents36 · Dec 2018 to Jun 2026
- Stockholders equity (US GAAP)36 · Dec 2018 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value35 · Sep 2019 to Jun 2026
- Allocated share based compensation expense35 · Sep 2019 to Jun 2026
- General and administrative expense (US GAAP)35 · Sep 2019 to Jun 2026
- Net income loss35 · Sep 2019 to Jun 2026
- Operating expenses (US GAAP)35 · Sep 2019 to Jun 2026
- Operating income loss35 · Sep 2019 to Jun 2026
- Research and development expense35 · Sep 2019 to Jun 2026
- Selling and marketing expense (US GAAP)35 · Sep 2019 to Jun 2026
- Amortization of financing costs34 · Dec 2019 to Jun 2026
- Amortization of intangible assets34 · Dec 2019 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect34 · Dec 2019 to Jun 2026
- Increase decrease in accounts payable trade34 · Dec 2019 to Jun 2026
- Increase decrease in inventories34 · Dec 2019 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets34 · Dec 2019 to Jun 2026
- Interest paid net34 · Dec 2019 to Jun 2026
- Net cash provided by used in financing activities34 · Dec 2019 to Jun 2026
- Net cash provided by used in operating activities34 · Dec 2019 to Jun 2026
- Profit loss34 · Dec 2019 to Jun 2026
- Share based compensation34 · Dec 2019 to Jun 2026
- Cost of goods and services sold (US GAAP)33 · Dec 2019 to Jun 2026
- Gross profit (US GAAP)33 · Dec 2019 to Jun 2026
Segment11 concepts · 142 facts · Dec 2022 to Jun 2026
- Allocated share based compensation expense14 · Dec 2022 to Jun 2026
- Depreciation and amortization14 · Dec 2022 to Jun 2026
- Income tax expense benefit14 · Dec 2022 to Jun 2026
- Interest expense nonoperating14 · Dec 2022 to Jun 2026
- Investment income nonoperating14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Rare Neurological Diseases Segment14 · Dec 2022 to Jun 2026
- Revenue14 · Dec 2022 to Jun 2026
- Segment reporting other item amount14 · Dec 2022 to Jun 2026
- Cost of goods and service excluding depreciation depletion and amortization13 · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)3 · Dec 2022 to Dec 2024
Guidance1 concepts · 30 facts · Jan 2024 to Aug 2026
- Revenue Guidance30 · Jan 2024 to Aug 2026
Product1 concepts · 13 facts · Dec 2019 to Jun 2022
- Cost of goods and services sold (US GAAP)13 · Dec 2019 to Jun 2022
Segments
155 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 142 facts
- Rare Neurological Diseases142 · Dec 2022 to Jun 2026
Product or service1 member · 13 facts
- Product13 · Dec 2019 to Jun 2022
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.